<DOC>
	<DOCNO>NCT01880320</DOCNO>
	<brief_summary>The study hypothesis base assumption : - CD0271 0.3 % /CD1579 2.5 % Gel provide superior clinical efficacy compare Topical Gel Vehicle overall population subgroup severe Subjects - CD0271 0.3 % /CD1579 2.5 % Gel apply daily 12 week acceptable safety tolerability profile</brief_summary>
	<brief_title>Multi-center , Randomized , Double-blind Efficacy Safety CD0271 0.3 % /CD1579 2.5 % Topical Gel Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>1 . Male female , 12 year age old Screening visit . 2 . Clinical diagnosis acne vulgaris facial involvement . 3 . An IGA Moderate ( 3 ) Severe ( 4 ) Baseline visit . 4 . A minimum 20 100 inflammatory lesion ( papule pustule ) face ( include nose ) Baseline visit . 5 . A minimum 30 150 noninflammatory lesion ( open comedo close comedo ) face ( include nose ) Baseline visit . 1 . More 2 acne nodule face Baseline visit . 2 . Acne conglobata , acne fulminans , secondary acne ( chloracne , druginduced acne , etc . ) , nodulo cystic acne , acne require systemic treatment . 3 . Underlying disease dermatologic condition require use interfering topical systemic therapy might interfere study assessment , limited , atopic dermatitis , perioral dermatitis rosacea . This include clinically significant abnormal finding , uncontrolled serious disease , medical surgical condition , may either interfere interpretation clinical trial result , and/or put subject significant risk ( accord Investigator 's judgment ) he/she participate clinical trial . 4 . The subject receive , apply take specified treatment within specify timeframe prior Baseline visit 5 . The subject unwilling refrain use prohibit medication clinical trial . 6 . Use hormonal contraceptive solely control acne .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>